Genomic drug developer Tessera Therapeutics raised $230m in a round co-led by SoftBank Vision Fund 2 as it works on its gene writing technology.

Telecommunications and internet conglomerate SoftBank’s Vision Fund 2 co-led a series B round for US-based genomic drug developer Tessera Therapeutics yesterday sized at more than $230m. The round was co-led by the state-owned Alaska Permanent Fund Corporation and venture capital firm Altitude Life Science Ventures, and it also featured sovereign wealth fund Qatar Investment Authority…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.